Science News
from research organizations

Alzheimer’s disease in men linked to low levels of hormone IGF-1

Date:
October 2, 2012
Source:
Endocrine Society
Summary:
Low serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) are associated with Alzheimer’s Disease in men, but not women, according to a recent study.
Share:
       
FULL STORY

Low serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) are associated with Alzheimer's Disease in men, but not women, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

IGF-1 and IGFBP-3 are involved in longevity and could be beneficial to cognition, especially in Alzheimer's disease where experimental studies have shown that IGF-1 opposes the main pathological processes of Alzheimer's disease. The current study investigated the relationship between IGF-1 and IGFBP-3 serum levels and cognitive impairment, including Alzheimer's disease.

"At this time, no curative treatment is available for Alzheimer's disease so focus on modifiable associated factors is of major importance," said Emmanuelle Duron, MD, PhD, of Broca Hospital in Paris, France and lead author of the study. "Our research shows a possible usefulness of IGF-1 in Alzheimer's disease treatment, especially in early stages."

In this multicentric cross-sectional study, researchers measured IGF-1 and IGFBP-3 serum levels in 694 elderly subjects (218 men and 476 women). Of the study participants, 481 had memory complaints and were diagnosed with Alzheimer's disease or mild cognitive impairment. Duron and her colleagues found that IGF-1 and IGFBP-3 serum levels were significantly associated with cognitive status in men, but not in women.

"Our cross-sectional association does not mean a causal relationship," notes Duron. "Our results justify a longitudinal study to evaluate whether circulating IGF-1/IGFBP-3 are predictive of cognitive decline according to gender."

Other researchers working on the study include: Benoit Funalot, Nadege Brunel, Cecile Viollet, Jacques Epelbaum and Yves le Bouc of Institut National de la Santé et de la Recherche Médicale (INSERM) in Paris France; Joel Coste and Laurent Quinquis of Hotel Dieu in Paris, France; Joel Belmin of Charles Foix Hospital in Seine, France; Pierre Jouanny of Centre Hospitalo in Amiens, France; Florence Pasquier of Hopital Roger Salengro in Lille, France; Jean-Marc Treluyer of France Unite de Recherche Clinique in Paris, France; and Olivier Hanon of Broca Hospital in Paris, France.


Story Source:

The above story is based on materials provided by Endocrine Society. Note: Materials may be edited for content and length.


Journal Reference:

  1. Duron E, Funalot B, Brunel N, Coste J, Quinquis L, Viollet C, Belmin J, Jouanny P, Pasquier F, Treluyer JM, Epelbaum J, le Bouc Y, Hanon O. Insulin-Like Growth Factor-I and Insulin-Like Growth Factor Binding Protein-3 in Alzheimer's Disease. J Clin Endocrinol Metab., 2012 Sep 26 [link]

Cite This Page:

Endocrine Society. "Alzheimer’s disease in men linked to low levels of hormone IGF-1." ScienceDaily. ScienceDaily, 2 October 2012. <www.sciencedaily.com/releases/2012/10/121002091759.htm>.
Endocrine Society. (2012, October 2). Alzheimer’s disease in men linked to low levels of hormone IGF-1. ScienceDaily. Retrieved May 24, 2015 from www.sciencedaily.com/releases/2012/10/121002091759.htm
Endocrine Society. "Alzheimer’s disease in men linked to low levels of hormone IGF-1." ScienceDaily. www.sciencedaily.com/releases/2012/10/121002091759.htm (accessed May 24, 2015).

Share This Page: